BeStock  

BioCryst Pharmaceuticals BCRX

US equityMarket cap rank #2720Drug Manufacturers - Specialty & Generic
$7.22 −$0.10 (-1.37%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.10 -1.66%
Open$7.26
Prev close$7.32
Day range$7.15 – $7.39
Volume3.85M
Market cap$1.86B
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

BCRX at a glance

Shares of BioCryst Pharmaceuticals are down 1.37% at $7.22. The company is worth $1.86B, number 2720 out of 3753 on our list.

Over the past 52 weeks it has traded between $6.23 and $11.22, so it sits 35.7% below the top of that range. Holders are ahead 3.6% over twelve months, but down 25.4% across the last three months.

On the chart it has slipped under both the 50-day ($8.08) and 200-day ($8.82) moving averages; RSI is 35, and the last 30 sessions moved at roughly 40% annualized volatility.

Revenue for the quarter ended Sep 2026 was $180.29M, up 13.1% from a year earlier, with $37.92M of net profit (a -37.4% margin).

6 analysts follow the stock and the average call is "buy". The mean target, $17.00, sits 135.5% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Key statistics

Bid / Ask$7.11 / $7.33
Average price today$7.25
Volume3.85MAvg (90d) 4.45M
Turnover$27.91M
Turnover rate1.61%of shares outstanding
Volume ratio1.13vs. recent average pace
Day amplitude3.35%
Market cap$1.86B
Float market cap$1.73B
Shares outstanding239.51M
EPS (TTM)$1.21
P/B-4.68
Book value / share-$1.54
Net profit (TTM)$311.33M
Net assets-$397.27M
30-day volatility40.4%annualized
Avg daily range (ATR)5.02%of price, 14 days
Max drawdown (1y)-35.0%-35.0% from 1y peak

Quote as of Nov 20, 2026 8:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

D
BeStock Grade

Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.

F
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

D
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

6 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Six-factor research snapshot

Overall percentile: 60.9 · 2026-11-22 14:27 UTC. Higher values indicate a stronger relative ranking.

FactorPercentile
Valuation68.8
Growth—
Profitability55.7
Momentum28.4
Financial health32.7
Analyst view71.0

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$17.00+135.5% vs. current price
Consensus ratingBuy6 analysts covering
Morningstar fair value$8.08Price is below fair value

Wall Street’s average 12-month target is $17.00, 135.5% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $8.08, so shares trade 10.6% below that estimate. On earnings multiple, it sits in the 70th percentile of its own five-year valuation range (pricier than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
-1.4%
1 week
-5.1%
1 month
-7.2%
3 months
-25.4%
6 months
-12.9%
Year to date
-7.4%
1 year
+3.6%
Day range
$7.15$7.39
52-week range
$6.23$11.22

Technical signals

Full technicals →
Trend readStrong downtrend

0 bullish · 7 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average-7.8%Bearish
Price vs 50-day average-10.7%Bearish
Price vs 200-day average-18.2%Bearish
50-day vs 200-day50d below 200dBearish
RSI (14)34.7Bearish
MACD (12,26,9)-0.25Bearish
Bollinger band position15%Bearish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How BCRX ranks on BeStock

Market value#2708 of 3734
Closeness to 52-week high#2477 of 3724
Dollar volume today#1801 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

BCRX is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on BCRX.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on BCRX

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

BCRX stock: common questions

What is BCRX's latest share price?

$7.22 is the latest print for BCRX, a move of -1.37% against yesterday's close of $7.32. Today's low and high so far: $7.15 and $7.39.

How big is BioCryst Pharmaceuticals?

Equity value comes to $1.86B at the current price. By that measure it is number 2720 of the 3753 names in our coverage.

Is BCRX near its 52-week high or low?

The year's floor is $6.23 and the ceiling $11.22. Shares are 35.7% away from that ceiling.

Does BioCryst Pharmaceuticals pay a dividend?

Our data shows no dividend paid by BioCryst Pharmaceuticals over the trailing twelve months.

Is BCRX rated a buy by Wall Street?

Of 6 analysts, 67% say buy, 33% hold and 0% sell. Price targets average $17.00, with the most cautious at $11.00 and the most optimistic at $30.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on BCRX.

Sign in to join the discussion.

Scroll to Top